Olga Issakova

Olga Issakova, Ph.D., is an accomplished entrepreneur with more than thirty years of broad experience in therapeutic drug discovery and development. She has an outstanding research record that highlights her commitment to innovation, and she is recognized globally as an international expert.

Dr. Issakova is a co-founder of Tailor Therapeutics, Inc., a life science company dedicated to the development of advanced technologies and next-generation chelators for radiopharmaceuticals. At Tailor Therapeutics, she currently holds the position of Chief Operating Officer, overseeing the company’s overall business strategy and operations.

Previously, she helped launch Nanosyn, Inc., a Bay Area CDMO. There, she was instrumental in advancing high-throughput purification systems and developing proprietary organic synthesis technology. As an Executive Vice President and later Chief Operating Officer, Dr. Issakova played a crucial role in guiding Nanosyn’s scientific vision as well as its business strategy. Her leadership contributed to growing the team from just three people into a multi-site company that was eventually acquired by a major international corporation. Additionally, she served as Chief Executive Officer at PCAS-NANOSYN, LLC., a joint venture between Nanosyn and PCAS—a leading French manufacturer of intermediates and APIs with multiple sites across Europe

Prior to that, Dr. Issakova held multiple management positions at Sanofi and served as a Member of the Senior Scientific Staff Committee.